Research team describes novel tumor treatment

November 24, 2015
Gliobastoma (astrocytoma) WHO grade IV - MRI coronal view, post contrast. 15 year old boy. Credit: Christaras A/ Wikipedia.

In the first published results from a $386,000 National Cancer Institute grant awarded earlier this year, a paper by Scott Verbridge and Rafael Davalos in Scientific Reports has been published.

The paper—co-written by John Rossmeisl , Virginia-Maryland College of Veterinary Medicine associate professor of internal medicine and neurology; Michael Sano, postdoctoral researcher at Stanford; and Virginia Tech Department of Biomedical Engineering and Mechanics Ph.D. students Jill Ivey of Fayetteville, Arkansas and Eduardo Latouche of Valencia, Venezuela,—describes the researchers' work on developing a new type of treatment for glioblastoma multiforme (GBM), the most common and deadly malignant primary brain tumor.

Patients with glioblastoma have a five-year survival rate of less than 10 percent, Verbridge said.

"This statistic has not improved significantly in decades, and there is still no treatment option to preferentially target the glioma stem cells or diffuse infiltrative cells that lead to tumor recurrence after surgery, chemo, or radiotherapy," Verbridge said.

The paper, "Targeted cellular ablation based on the morphology of malignant cells," describes research into a new treatment option involving pulsed electric fields (PEFs) that is better at targeting and killing malignant cells while leaving alive.

Glioblastoma is particularly resistant to conventional and targeted cancer therapies, in part because tumors are made up of cells that are very different from one another. Surgical, chemical, radiation, and molecular treatments all have shortcomings that make it difficult to target malignant cells without damaging critical surrounding structures or prompting the emergence of therapy-resistant cells.

Recurrence after initial treatment is extremely common as a result.

In their work, Verbridge and Davalos are building on a technique patented by Davalos involving irreversible electroporation (IRE) of tumor cells by inserting electrodes directly into a tumor. This treatment has been successfully used to treat canine patients with similar brain tumors.

Verbridge and Davalos have developed a high-frequency version of this therapy (HFIRE) that uses pulses delivered in a rapid burst. IRE and HFIRE are both capable of killing tumor cells, but the mechanism differs, the researchers found. IRE appears to cause cellular death by disrupting the outer cell membrane. HFIRE, in contrast, appears to also cause nuclear collapse. Mathematical models developed by the researchers predicted that the nuclear damage should scale with size of the nucleus relative to the cell.

Because HFIRE targets the nucleus, the researchers hypothesized that malignant cells, which have larger nuclei compared to in many cancers including glioblastoma, would have a lower threshold for a lethal burst.

Therefore, properly tuned HFIRE could target while leaving normal, healthy cells unharmed.

This was confirmed using 3-D tissue models consisting of co-cultures of normal and malignant brain cells. "We're essentially destroying based on their altered morphologies, specifically their enlarged nucleus-to-cytoplasm ratio which has been known for decades to be a strong indicator of malignancy in many cancers. This is a completely different potential approach to targeted therapy," Verbridge said.

Future experiments in vivo will be necessary to determine exactly how selective HFIRE ablation therapy will be, but the researchers expressed confidence that such a therapy, either on its own or in combination with other treatments, could be effective at killing the invasive glioblastoma that so often lead to tumor recurrence after initial rounds of treatment.

Explore further: Dog's successful surgery sets stage for treating humans

More information: Targeted cellular ablation based on the morphology of malignant cells, Scientific Reports, 2015.

Related Stories

Dog's successful surgery sets stage for treating humans

February 19, 2015
Almost five years ago, a 7-year-old Labrador retriever was operated on using a technique eventually patented by Virginia Tech biomedical engineering faculty member Rafael Davalos. The beloved family pet suffer from a cancerous ...

Researchers create a promising new treatment for the deadliest form of brain cancer

September 2, 2015
UCLA scientists have developed a potentially promising new combination therapy for glioblastoma, the most common and deadliest form of brain cancer.

Researchers find way to make resistant brain cancer cells sensitive to treatment

November 16, 2015
Scientists from the Virginia Tech Carilion Research Institute and clinicians from Carilion Clinic have discovered how to sensitize drug-resistant human glioblastoma cells to chemotherapy.

Virus-drug combination shows improved effectiveness against brain tumor cells

October 6, 2015
A rabbit virus currently being developed for cancer therapy can be paired with one of several existing drugs to deliver a more potent punch to a deadly type of brain tumor cell, researchers have found.

Researchers target cancer stem cells in malignant brain tumors

January 6, 2014
Researchers at the Cedars-Sinai Maxine Dunitz Neurosurgical Institute and Department of Neurosurgery identified immune system targets on cancer stem cells – cells from which malignant brain tumors are believed to originate ...

Team identifies drug that could limit the spread of deadly brain tumors

November 12, 2015
In a significant breakthrough, the Translational Genomics Research Institute (TGen) has identified a drug, propentofylline or PPF, that could help treat patients with deadly brain cancer.

Recommended for you

Scientists develop blood test that spots tumor-derived DNA in people with early-stage cancers

August 16, 2017
In a bid to detect cancers early and in a noninvasive way, scientists at the Johns Hopkins Kimmel Cancer Center report they have developed a test that spots tiny amounts of cancer-specific DNA in blood and have used it to ...

Researchers find 'switch' that turns on immune cells' tumor-killing ability

August 16, 2017
Molecular biologists led by Leonid Pobezinsky and his wife and research collaborator Elena Pobezinskaya at the University of Massachusetts Amherst have published results that for the first time show how a microRNA molecule ...

Cell cycle-blocking drugs can shrink tumors by enlisting immune system in attack on cancer

August 16, 2017
In the brief time that drugs known as CDK4/6 inhibitors have been approved for the treatment of metastatic breast cancer, doctors have made a startling observation: in certain patients, the drugs—designed to halt cancer ...

Toxic formaldehyde is produced inside our own cells, scientists discover

August 16, 2017
New research has revealed that some of the toxin formaldehyde in our bodies does not come from our environment - it is a by-product of an essential reaction inside our own cells. This could provide new targets for developing ...

Popular immunotherapy target turns out to have a surprising buddy

August 16, 2017
The majority of current cancer immunotherapies focus on PD-L1. This well studied protein turns out to be controlled by a partner, CMTM6, a previously unexplored molecule that is now suddenly also a potential therapeutic target. ...

A metabolic treatment for pancreatic cancer?

August 15, 2017
Pancreatic cancer is now the third leading cause of cancer mortality. Its incidence is increasing in parallel with the population increase in obesity, and its five-year survival rate still hovers at just 8 to 9 percent. Research ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.